{
  "markdown": "<a id='3f54f31e-3b98-417a-b58d-c922a51d7226'></a>\n\n# A Brief History of PN\n\n<a id='8acd1fbd-3607-445e-b3dc-15e9929d084f'></a>\n\nNASPGHAN\nFOUNDATION\n\n<a id='520d7eab-0eef-4d8f-a453-03286f279db4'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, bold, italicized text \"NASPGHAN\" on a light blue gradient background, with a dark blue curved swoosh underneath.::>\n\n<a id='57c4d597-1e7b-460a-bee6-192c9d290caa'></a>\n\n# History of PN in North America\n\n* Requirements for PN\n    * Appropriate venous access\n    * Appropriate intravenous nutrient solutions\n\n<a id='91e9380a-870d-420b-a804-505ed9f77621'></a>\n\n* 1930's\n    * Protein hydrolysate solutions available (high immunogenicity)\n\n<a id='1d398029-7157-410a-a327-5d9d01840ab5'></a>\n\n<::Two black and white photographs of infants. The top photo shows an infant lying on its back, with its right arm raised and left arm by its side. The infant appears to be very thin, with visible ribs and some skin markings. It is lying on a white cloth in what looks like an incubator or medical bed. The bottom photo shows another infant, also lying on its back, looking towards the viewer. This infant also appears to be in a medical setting, possibly an incubator, with its arms bent and legs slightly spread. Both infants appear to be newborns or very young babies.: figure::>\n\n<a id='5ed7dce7-95b0-41de-a2e0-2bd5cdec94ef'></a>\n\n* 1960's\n  * Safe intravenous fat emulsion preparation (Europe only)\n  * Seldinger technique for central venous access\n  * 1968: First clinical report of long-term PN support in beagle puppies\n  * 1968: First case report of preterm infant maintained for 44 days on intravenous nutrition\n\n<a id='03c89d84-d003-4ca1-a745-707480437870'></a>\n\n<::NASPGHAN\nFOUNDATION\n: figure::>\n\n<a id='8a082dbe-c1f1-4f3f-971f-ec5f982921b8'></a>\n\nCAPTION ERROR\n\n<a id='bbe3d4a3-fc83-43c5-99cd-20c39938a951'></a>\n\n# History of PN in North America – Cont'd\n\n*   1970's\n    *   Crystalline amino acid solutions available\n        (decreased immunogenic reactions)\n*   1980's\n    *   Infant-specific crystalline amino acid solutions\n    *   Alternative lipid emulsions developed in Europe\n    *   American Medical Association Nutrition Advisory Group recommendations\n        for intravenous vitamins\n\n<a id='28ff2e34-7a2d-42bc-bc94-db7f0c510313'></a>\n\n<::NASPGHAN FOUNDATION logo::>\n\n<a id='c7feccd7-5841-4c47-89f5-04d54f655839'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features the bold, italicized, dark blue text \"NASPGHAN\" on a blue gradient background, underlined by a dark blue curved swoosh.::>\n\n<a id='25592993-d23e-4a64-b0cf-ee2d94861170'></a>\n\nHistory of PN in North America – Cont’d\n\n* 2000's\n  * 2002 – USA Food and Drug Administration (FDA) pediatrics approval for Intralipid®\n* 2010's\n  * 2016 – Health Canada pediatric approval for SMOFLipid®\n  * 2018 – FDA pediatric approval for Omegaven®\n* 2020's\n  * 2022 – FDA pediatric approval for SMOFLipid®\n  * 2024 - FDA pediatric approval for CLINOLIPID®\n\n<a id='8e5f7951-ffca-4ba5-8d3a-58bf13791d65'></a>\n\n<::NASPGHAN FOUNDATION logo with a blue gradient background.: figure::>\n\n<a id='32e448c3-f77c-47be-989f-5d0a5d255397'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, italicized, bold text \"NASPGHAN\" on a blue gradient background with a sweeping dark blue curved line underneath.::>",
  "chunks": [
    {
      "markdown": "<a id='3f54f31e-3b98-417a-b58d-c922a51d7226'></a>\n\n# A Brief History of PN",
      "type": "text",
      "id": "3f54f31e-3b98-417a-b58d-c922a51d7226",
      "grounding": {
        "box": {
          "left": 0.06456410884857178,
          "top": 0.39845889806747437,
          "right": 0.6186062693595886,
          "bottom": 0.5249052047729492
        },
        "page": 0
      }
    },
    {
      "markdown": "<a id='8acd1fbd-3607-445e-b3dc-15e9929d084f'></a>\n\nNASPGHAN\nFOUNDATION",
      "type": "text",
      "id": "8acd1fbd-3607-445e-b3dc-15e9929d084f",
      "grounding": {
        "box": {
          "left": -5.5767595767974854e-05,
          "top": 0.8960989117622375,
          "right": 0.15463075041770935,
          "bottom": 0.999728262424469
        },
        "page": 0
      }
    },
    {
      "markdown": "<a id='520d7eab-0eef-4d8f-a453-03286f279db4'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, bold, italicized text \"NASPGHAN\" on a light blue gradient background, with a dark blue curved swoosh underneath.::>",
      "type": "logo",
      "id": "520d7eab-0eef-4d8f-a453-03286f279db4",
      "grounding": {
        "box": {
          "left": 0.8060022592544556,
          "top": 0.8959396481513977,
          "right": 0.9981125593185425,
          "bottom": 0.9998850226402283
        },
        "page": 0
      }
    },
    {
      "markdown": "<a id='57c4d597-1e7b-460a-bee6-192c9d290caa'></a>\n\n# History of PN in North America\n\n* Requirements for PN\n    * Appropriate venous access\n    * Appropriate intravenous nutrient solutions",
      "type": "text",
      "id": "57c4d597-1e7b-460a-bee6-192c9d290caa",
      "grounding": {
        "box": {
          "left": 0.0653209388256073,
          "top": 0.09799501299858093,
          "right": 0.6189637184143066,
          "bottom": 0.3723171353340149
        },
        "page": 1
      }
    },
    {
      "markdown": "<a id='91e9380a-870d-420b-a804-505ed9f77621'></a>\n\n* 1930's\n    * Protein hydrolysate solutions available (high immunogenicity)",
      "type": "text",
      "id": "91e9380a-870d-420b-a804-505ed9f77621",
      "grounding": {
        "box": {
          "left": 0.06051930785179138,
          "top": 0.3846074938774109,
          "right": 0.5444811582565308,
          "bottom": 0.5551491379737854
        },
        "page": 1
      }
    },
    {
      "markdown": "<a id='1d398029-7157-410a-a327-5d9d01840ab5'></a>\n\n<::Two black and white photographs of infants. The top photo shows an infant lying on its back, with its right arm raised and left arm by its side. The infant appears to be very thin, with visible ribs and some skin markings. It is lying on a white cloth in what looks like an incubator or medical bed. The bottom photo shows another infant, also lying on its back, looking towards the viewer. This infant also appears to be in a medical setting, possibly an incubator, with its arms bent and legs slightly spread. Both infants appear to be newborns or very young babies.: figure::>",
      "type": "figure",
      "id": "1d398029-7157-410a-a327-5d9d01840ab5",
      "grounding": {
        "box": {
          "left": 0.7243578433990479,
          "top": 0.23111280798912048,
          "right": 0.9423040151596069,
          "bottom": 0.6686917543411255
        },
        "page": 1
      }
    },
    {
      "markdown": "<a id='5ed7dce7-95b0-41de-a2e0-2bd5cdec94ef'></a>\n\n* 1960's\n  * Safe intravenous fat emulsion preparation (Europe only)\n  * Seldinger technique for central venous access\n  * 1968: First clinical report of long-term PN support in beagle puppies\n  * 1968: First case report of preterm infant maintained for 44 days on intravenous nutrition",
      "type": "text",
      "id": "5ed7dce7-95b0-41de-a2e0-2bd5cdec94ef",
      "grounding": {
        "box": {
          "left": 0.05408927798271179,
          "top": 0.5786933302879333,
          "right": 0.8341571092605591,
          "bottom": 0.8638356328010559
        },
        "page": 1
      }
    },
    {
      "markdown": "<a id='03c89d84-d003-4ca1-a745-707480437870'></a>\n\n<::NASPGHAN\nFOUNDATION\n: figure::>",
      "type": "figure",
      "id": "03c89d84-d003-4ca1-a745-707480437870",
      "grounding": {
        "box": {
          "left": 0.00024703145027160645,
          "top": 0.8930197358131409,
          "right": 0.1578507274389267,
          "bottom": 0.9998350739479065
        },
        "page": 1
      }
    },
    {
      "markdown": "<a id='8a082dbe-c1f1-4f3f-971f-ec5f982921b8'></a>\n\nCAPTION ERROR",
      "type": "logo",
      "id": "8a082dbe-c1f1-4f3f-971f-ec5f982921b8",
      "grounding": {
        "box": {
          "left": 0.8022590279579163,
          "top": 0.8918474912643433,
          "right": 0.9990078806877136,
          "bottom": 0.999618411064148
        },
        "page": 1
      }
    },
    {
      "markdown": "<a id='bbe3d4a3-fc83-43c5-99cd-20c39938a951'></a>\n\n# History of PN in North America – Cont'd\n\n*   1970's\n    *   Crystalline amino acid solutions available\n        (decreased immunogenic reactions)\n*   1980's\n    *   Infant-specific crystalline amino acid solutions\n    *   Alternative lipid emulsions developed in Europe\n    *   American Medical Association Nutrition Advisory Group recommendations\n        for intravenous vitamins",
      "type": "text",
      "id": "bbe3d4a3-fc83-43c5-99cd-20c39938a951",
      "grounding": {
        "box": {
          "left": 0.06447094678878784,
          "top": 0.09575653076171875,
          "right": 0.9337890148162842,
          "bottom": 0.7349122762680054
        },
        "page": 2
      }
    },
    {
      "markdown": "<a id='28ff2e34-7a2d-42bc-bc94-db7f0c510313'></a>\n\n<::NASPGHAN FOUNDATION logo::>",
      "type": "figure",
      "id": "28ff2e34-7a2d-42bc-bc94-db7f0c510313",
      "grounding": {
        "box": {
          "left": -2.2426247596740723e-05,
          "top": 0.8989738821983337,
          "right": 0.15383972227573395,
          "bottom": 0.9992114901542664
        },
        "page": 2
      }
    },
    {
      "markdown": "<a id='c7feccd7-5841-4c47-89f5-04d54f655839'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features the bold, italicized, dark blue text \"NASPGHAN\" on a blue gradient background, underlined by a dark blue curved swoosh.::>",
      "type": "logo",
      "id": "c7feccd7-5841-4c47-89f5-04d54f655839",
      "grounding": {
        "box": {
          "left": 0.8057711720466614,
          "top": 0.8961002826690674,
          "right": 0.9984583258628845,
          "bottom": 0.9995905160903931
        },
        "page": 2
      }
    },
    {
      "markdown": "<a id='25592993-d23e-4a64-b0cf-ee2d94861170'></a>\n\nHistory of PN in North America – Cont’d\n\n* 2000's\n  * 2002 – USA Food and Drug Administration (FDA) pediatrics approval for Intralipid®\n* 2010's\n  * 2016 – Health Canada pediatric approval for SMOFLipid®\n  * 2018 – FDA pediatric approval for Omegaven®\n* 2020's\n  * 2022 – FDA pediatric approval for SMOFLipid®\n  * 2024 - FDA pediatric approval for CLINOLIPID®",
      "type": "text",
      "id": "25592993-d23e-4a64-b0cf-ee2d94861170",
      "grounding": {
        "box": {
          "left": 0.06732675433158875,
          "top": 0.09638586640357971,
          "right": 0.836391806602478,
          "bottom": 0.8599628210067749
        },
        "page": 3
      }
    },
    {
      "markdown": "<a id='8e5f7951-ffca-4ba5-8d3a-58bf13791d65'></a>\n\n<::NASPGHAN FOUNDATION logo with a blue gradient background.: figure::>",
      "type": "figure",
      "id": "8e5f7951-ffca-4ba5-8d3a-58bf13791d65",
      "grounding": {
        "box": {
          "left": -3.1925737857818604e-05,
          "top": 0.8980174660682678,
          "right": 0.15702193975448608,
          "bottom": 0.9996146559715271
        },
        "page": 3
      }
    },
    {
      "markdown": "<a id='32e448c3-f77c-47be-989f-5d0a5d255397'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, italicized, bold text \"NASPGHAN\" on a blue gradient background with a sweeping dark blue curved line underneath.::>",
      "type": "logo",
      "id": "32e448c3-f77c-47be-989f-5d0a5d255397",
      "grounding": {
        "box": {
          "left": 0.8048761487007141,
          "top": 0.8955257534980774,
          "right": 0.9984263777732849,
          "bottom": 0.9997450709342957
        },
        "page": 3
      }
    }
  ],
  "splits": [
    {
      "class": "full",
      "identifier": "full",
      "pages": [
        0,
        1,
        2,
        3
      ],
      "markdown": "<a id='3f54f31e-3b98-417a-b58d-c922a51d7226'></a>\n\n# A Brief History of PN\n\n<a id='8acd1fbd-3607-445e-b3dc-15e9929d084f'></a>\n\nNASPGHAN\nFOUNDATION\n\n<a id='520d7eab-0eef-4d8f-a453-03286f279db4'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, bold, italicized text \"NASPGHAN\" on a light blue gradient background, with a dark blue curved swoosh underneath.::>\n\n<a id='57c4d597-1e7b-460a-bee6-192c9d290caa'></a>\n\n# History of PN in North America\n\n* Requirements for PN\n    * Appropriate venous access\n    * Appropriate intravenous nutrient solutions\n\n<a id='91e9380a-870d-420b-a804-505ed9f77621'></a>\n\n* 1930's\n    * Protein hydrolysate solutions available (high immunogenicity)\n\n<a id='1d398029-7157-410a-a327-5d9d01840ab5'></a>\n\n<::Two black and white photographs of infants. The top photo shows an infant lying on its back, with its right arm raised and left arm by its side. The infant appears to be very thin, with visible ribs and some skin markings. It is lying on a white cloth in what looks like an incubator or medical bed. The bottom photo shows another infant, also lying on its back, looking towards the viewer. This infant also appears to be in a medical setting, possibly an incubator, with its arms bent and legs slightly spread. Both infants appear to be newborns or very young babies.: figure::>\n\n<a id='5ed7dce7-95b0-41de-a2e0-2bd5cdec94ef'></a>\n\n* 1960's\n  * Safe intravenous fat emulsion preparation (Europe only)\n  * Seldinger technique for central venous access\n  * 1968: First clinical report of long-term PN support in beagle puppies\n  * 1968: First case report of preterm infant maintained for 44 days on intravenous nutrition\n\n<a id='03c89d84-d003-4ca1-a745-707480437870'></a>\n\n<::NASPGHAN\nFOUNDATION\n: figure::>\n\n<a id='8a082dbe-c1f1-4f3f-971f-ec5f982921b8'></a>\n\nCAPTION ERROR\n\n<a id='bbe3d4a3-fc83-43c5-99cd-20c39938a951'></a>\n\n# History of PN in North America – Cont'd\n\n*   1970's\n    *   Crystalline amino acid solutions available\n        (decreased immunogenic reactions)\n*   1980's\n    *   Infant-specific crystalline amino acid solutions\n    *   Alternative lipid emulsions developed in Europe\n    *   American Medical Association Nutrition Advisory Group recommendations\n        for intravenous vitamins\n\n<a id='28ff2e34-7a2d-42bc-bc94-db7f0c510313'></a>\n\n<::NASPGHAN FOUNDATION logo::>\n\n<a id='c7feccd7-5841-4c47-89f5-04d54f655839'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features the bold, italicized, dark blue text \"NASPGHAN\" on a blue gradient background, underlined by a dark blue curved swoosh.::>\n\n<a id='25592993-d23e-4a64-b0cf-ee2d94861170'></a>\n\nHistory of PN in North America – Cont’d\n\n* 2000's\n  * 2002 – USA Food and Drug Administration (FDA) pediatrics approval for Intralipid®\n* 2010's\n  * 2016 – Health Canada pediatric approval for SMOFLipid®\n  * 2018 – FDA pediatric approval for Omegaven®\n* 2020's\n  * 2022 – FDA pediatric approval for SMOFLipid®\n  * 2024 - FDA pediatric approval for CLINOLIPID®\n\n<a id='8e5f7951-ffca-4ba5-8d3a-58bf13791d65'></a>\n\n<::NASPGHAN FOUNDATION logo with a blue gradient background.: figure::>\n\n<a id='32e448c3-f77c-47be-989f-5d0a5d255397'></a>\n\n<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, italicized, bold text \"NASPGHAN\" on a blue gradient background with a sweeping dark blue curved line underneath.::>",
      "chunks": [
        "3f54f31e-3b98-417a-b58d-c922a51d7226",
        "8acd1fbd-3607-445e-b3dc-15e9929d084f",
        "520d7eab-0eef-4d8f-a453-03286f279db4",
        "57c4d597-1e7b-460a-bee6-192c9d290caa",
        "91e9380a-870d-420b-a804-505ed9f77621",
        "1d398029-7157-410a-a327-5d9d01840ab5",
        "5ed7dce7-95b0-41de-a2e0-2bd5cdec94ef",
        "03c89d84-d003-4ca1-a745-707480437870",
        "8a082dbe-c1f1-4f3f-971f-ec5f982921b8",
        "bbe3d4a3-fc83-43c5-99cd-20c39938a951",
        "28ff2e34-7a2d-42bc-bc94-db7f0c510313",
        "c7feccd7-5841-4c47-89f5-04d54f655839",
        "25592993-d23e-4a64-b0cf-ee2d94861170",
        "8e5f7951-ffca-4ba5-8d3a-58bf13791d65",
        "32e448c3-f77c-47be-989f-5d0a5d255397"
      ]
    }
  ],
  "grounding": {
    "3f54f31e-3b98-417a-b58d-c922a51d7226": {
      "box": {
        "left": 0.06456410884857178,
        "top": 0.39845889806747437,
        "right": 0.6186062693595886,
        "bottom": 0.5249052047729492
      },
      "page": 0,
      "type": "chunkText"
    },
    "8acd1fbd-3607-445e-b3dc-15e9929d084f": {
      "box": {
        "left": -5.5767595767974854e-05,
        "top": 0.8960989117622375,
        "right": 0.15463075041770935,
        "bottom": 0.999728262424469
      },
      "page": 0,
      "type": "chunkText"
    },
    "520d7eab-0eef-4d8f-a453-03286f279db4": {
      "box": {
        "left": 0.8060022592544556,
        "top": 0.8959396481513977,
        "right": 0.9981125593185425,
        "bottom": 0.9998850226402283
      },
      "page": 0,
      "type": "chunkLogo"
    },
    "57c4d597-1e7b-460a-bee6-192c9d290caa": {
      "box": {
        "left": 0.0653209388256073,
        "top": 0.09799501299858093,
        "right": 0.6189637184143066,
        "bottom": 0.3723171353340149
      },
      "page": 1,
      "type": "chunkText"
    },
    "91e9380a-870d-420b-a804-505ed9f77621": {
      "box": {
        "left": 0.06051930785179138,
        "top": 0.3846074938774109,
        "right": 0.5444811582565308,
        "bottom": 0.5551491379737854
      },
      "page": 1,
      "type": "chunkText"
    },
    "1d398029-7157-410a-a327-5d9d01840ab5": {
      "box": {
        "left": 0.7243578433990479,
        "top": 0.23111280798912048,
        "right": 0.9423040151596069,
        "bottom": 0.6686917543411255
      },
      "page": 1,
      "type": "chunkFigure"
    },
    "5ed7dce7-95b0-41de-a2e0-2bd5cdec94ef": {
      "box": {
        "left": 0.05408927798271179,
        "top": 0.5786933302879333,
        "right": 0.8341571092605591,
        "bottom": 0.8638356328010559
      },
      "page": 1,
      "type": "chunkText"
    },
    "03c89d84-d003-4ca1-a745-707480437870": {
      "box": {
        "left": 0.00024703145027160645,
        "top": 0.8930197358131409,
        "right": 0.1578507274389267,
        "bottom": 0.9998350739479065
      },
      "page": 1,
      "type": "chunkFigure"
    },
    "8a082dbe-c1f1-4f3f-971f-ec5f982921b8": {
      "box": {
        "left": 0.8022590279579163,
        "top": 0.8918474912643433,
        "right": 0.9990078806877136,
        "bottom": 0.999618411064148
      },
      "page": 1,
      "type": "chunkLogo"
    },
    "bbe3d4a3-fc83-43c5-99cd-20c39938a951": {
      "box": {
        "left": 0.06447094678878784,
        "top": 0.09575653076171875,
        "right": 0.9337890148162842,
        "bottom": 0.7349122762680054
      },
      "page": 2,
      "type": "chunkText"
    },
    "28ff2e34-7a2d-42bc-bc94-db7f0c510313": {
      "box": {
        "left": -2.2426247596740723e-05,
        "top": 0.8989738821983337,
        "right": 0.15383972227573395,
        "bottom": 0.9992114901542664
      },
      "page": 2,
      "type": "chunkFigure"
    },
    "c7feccd7-5841-4c47-89f5-04d54f655839": {
      "box": {
        "left": 0.8057711720466614,
        "top": 0.8961002826690674,
        "right": 0.9984583258628845,
        "bottom": 0.9995905160903931
      },
      "page": 2,
      "type": "chunkLogo"
    },
    "25592993-d23e-4a64-b0cf-ee2d94861170": {
      "box": {
        "left": 0.06732675433158875,
        "top": 0.09638586640357971,
        "right": 0.836391806602478,
        "bottom": 0.8599628210067749
      },
      "page": 3,
      "type": "chunkText"
    },
    "8e5f7951-ffca-4ba5-8d3a-58bf13791d65": {
      "box": {
        "left": -3.1925737857818604e-05,
        "top": 0.8980174660682678,
        "right": 0.15702193975448608,
        "bottom": 0.9996146559715271
      },
      "page": 3,
      "type": "chunkFigure"
    },
    "32e448c3-f77c-47be-989f-5d0a5d255397": {
      "box": {
        "left": 0.8048761487007141,
        "top": 0.8955257534980774,
        "right": 0.9984263777732849,
        "bottom": 0.9997450709342957
      },
      "page": 3,
      "type": "chunkLogo"
    }
  },
  "metadata": {
    "filename": "2PN History.pdf",
    "org_id": null,
    "page_count": 4,
    "duration_ms": 6811,
    "credit_usage": 12.0,
    "job_id": "flt72nykeb24lb2gdbznszo5g",
    "version": "dpt-2-20250919"
  }
}